ResQ Biotech

Executive Summary

ResQ Biotech is a European biotechnology start-up headquartered in Helsinki, Finland, founded in 2017 with a mission to discover novel therapeutics for diseases caused by protein misfolding and aggregation. The company's proprietary platform enables rapid screening of molecular libraries to identify drug leads, with initial focus on neurodegenerative disorders such as Alzheimer's, ALS, and Parkinson's. In parallel, ResQ develops proprietary research tools to support basic and applied scientific investigations, potentially expanding its revenue streams and strategic partnerships. Despite being at an early stage with no disclosed pipeline or funding details, the company's platform approach and focus on high-need indications position it within a competitive but promising space. ResQ's private status and limited public data suggest it is still in the preclinical or discovery phase, likely seeking to advance lead candidates toward IND-enabling studies.

Upcoming Catalysts (preview)

• Q3 2026Lead Candidate Nomination for Neurodegenerative Program40% success
• Q4 2026Series A Funding Announcement50% success
• H2 2026Research Tool Commercialization Partnership60% success